Title:
CHIMERIC ANTIGEN RECEPTOR-MODIFIED T CELL TARGETING MESOTHELIN AND USE THEREOF
Document Type and Number:
WIPO Patent Application WO/2019/020088
Kind Code:
A1
Abstract:
Provided in the present invention are a chimeric antigen receptor targeting mesothelin and the use thereof. The chimeric antigen receptor provided by the present invention, from the N-terminus to the C-terminus, successively comprises a membrane protein signal peptide, a single-chain antibody combating the membrane proximal end of mesothelin, a hinge region of more than 50 amino acid residues, a transmembrane region, a co-stimulatory signal molecule intracellular domain and an immunoreceptor tyrosine-based activation motif. Also provided in the present invention is a T cell expressing the chimeric antigen receptor. The T cell can specifically kill tumour cell lines with a high expression of mesothelin, and has little or no killing effect on tumour cell lines which do not express mesothelin, and has a good specificity.
Inventors:
QIAN QIJUN (CN)
JIN HUAJUN (CN)
JIANG DUQING (CN)
WANG CHAO (CN)
CUI LIANZHEN (CN)
LI LINFANG (CN)
JIN HUAJUN (CN)
JIANG DUQING (CN)
WANG CHAO (CN)
CUI LIANZHEN (CN)
LI LINFANG (CN)
Application Number:
PCT/CN2018/097307
Publication Date:
January 31, 2019
Filing Date:
July 27, 2018
Export Citation:
Assignee:
SHANGHAI CELL THERAPY RES INST (CN)
SHANGHAI CELL THERAPY GROUP CO LTD (CN)
SHANGHAI CELL THERAPY GROUP CO LTD (CN)
International Classes:
C07K19/00; A61K35/17; A61P35/00; C12N5/10; C12N15/62; C12N15/63
Foreign References:
| CN106459989A | 2017-02-22 | |||
| CN106543288A | 2017-03-29 | |||
| CN105026429A | 2015-11-04 |
Attorney, Agent or Firm:
SHANGHAI PATENT & TRADEMARK LAW OFFICE, LLC. (CN)
Download PDF: